Market Newsdesk

Jinhua, China , Jan. 13, 2026 (GLOBE NEWSWIRE) — Kandi Technologies Group, Inc. (“Kandi”, “Kandi Technologies”, or the “Company”) (NASDAQ GS: KNDI), a long renowned leader in all-electric personal transportation and utility vehicles, today announced its participation in American International Motorcycle Expo (“AIMExpo”) for the year 2026, held from January 7 to 9, 2026 at the Anaheim Convention Center in California. During the event, Kandi showcased its core lineup of electric off-road vehicle products tailored for the North American market and engaged in strategic discussions with existing dealers and prospective channel partners. Through on-site product demonstrations and targeted business meetings, the Company further strengthened its channel network and explored new collaboration opportunities to drive continued market expansion.

As one of the most influential trade shows in the North American powersports industry, AIMExpo brings together global leading manufacturers, distributors, and industry professionals. Kandi highlighted several flagship products at the event, including crossover electric golf carts such as the Element 2+2, 4Pro F, and 6Pro 4+2, as well as electric UTV models from the Cowboy and Innovator series. Designed to address diverse applications — from community mobility and agricultural operations to outdoor recreation — these vehicles demonstrate Kandi’s market readiness, engineering expertise, and deep understanding of end-user needs in North America.

Kandi Technologies’ Electric Off-road Vehicles at AIMExpo 2026: 

Crossover Electric Golf Cart (L), Electric UTV (R).

Throughout the event, the Kandi team held extensive discussions with dealers and potential partners regarding product roadmaps, market demand trends, and cooperation models. As a result of these engagements, the Company successfully formalized collaboration agreements with multiple new channel partners, laying a solid foundation for future market penetration and business execution.

Mr. Feng Chen, CEO of Kandi, commented: “North America remains one of the core strategic markets for our electric off-road vehicle business. By consistently participating in leading industry events like AIMExpo, we are able to strengthen collaboration with channel partners, sharpen our market insights, and ensure our products optimally align with our distribution network. This event not only reinforced our existing partnerships but also created new avenues for future growth. Looking ahead, we remain focused on the North American market, steadily advancing product evolution, channel development, and localized operations to support sustainable long-term growth.”

Over the years, Kandi has invested continuously to establish a comprehensive localized operational ecosystem in North America, spanning product development, manufacturing, supply chain management, and channel operations. The Company maintains a production facility and multiple distribution centers in the United States, allowing it to optimize its product mix and channel strategy based on local market needs. The successful participation in AIMExpo 2026 is expected to further enhance Kandi’s industry visibility within the North American powersports and off-road vehicle sectors, supporting the Company’s long-term business development.

Safe Harbor Statement

This press release contains certain statements that may include “forward-looking statements.” All statements other than statements of historical fact included herein are “forward-looking statements.” These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including the risk factors discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on the SEC’s website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Other than as required under the applicable securities laws, the Company does not assume a duty to update these forward-looking statements.

About Kandi Technologies Group, Inc.

Kandi Technologies Group, Inc. (NASDAQ GS: KNDI) is a leader in the research, development, and manufacturing of all-electric personal transportation and utility vehicles. Headquartered in Jinhua, China, the Company’s primary focus is on off-road mobility solutions, with a strategic emphasis for the North American market, while actively pursuing opportunities in other related emerging high-tech areas. Through its subsidiaries, Kandi Technologies leverages its robust manufacturing capabilities and technological expertise to deliver innovative products for a wide range of commercial and consumer applications.

For more information, please visit ir.kandigroup.com

For investor and media inquiries, please contact:

Kandi Technologies Group, Inc.
Kewa Luo
Tel: +1 (212) 551-3610
Email: [email protected]

Piacente Financial Communications
Brandi Piacente
Tel: +86-10-6508-0677
Email: [email protected]

January 13, 2026, 7:00 AM CET 

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a supplemental Biologics License Application (sBLA) for VYVGART® (IV: efgartigimod alfa-fcab) for the treatment of adults with acetylcholine receptor antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). The application has been granted a Prescription Drug User Fee Act (PDUFA) target action date of May 10, 2026.

“Patients living with seronegative gMG continue to face limited treatment options and there remains a significant need to meaningfully improve their lives. The FDA’s acceptance of our sBLA with Priority Review status reflects the potential of VYVGART to address this need,” said Luc Truyen, M.D., Ph.D., Chief Medical Officer, argenx. “This development brings us closer to expanding the use of VYVGART in a broad spectrum of patients with myasthenia gravis. We look forward to continuing our dialogue with the FDA as they review our application.”

The sBLA is supported by data from the Phase 3 ADAPT SERON study, which evaluated the efficacy and safety of VYVGART in adults with AChR-Ab seronegative gMG across all three subtypes – MuSK+, LRP4+, and triple seronegative gMG. The study met its primary endpoint (p-value=0.0068), demonstrating a statistically significant improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score compared to placebo after four weeks.

In the overall population, mean change from baseline in patients treated with VYVGART was a clinically meaningful 3.35 point improvement in MG-ADL total score at week 4. Improvements in MG-ADL and Quantitative Myasthenia Gravis (QMG) scores were observed across subsequent treatment cycles in the overall population and in all patient subgroups, including MuSK+, LRP4+, and triple seronegative gMG.

VYVGART was well-tolerated with a safety profile consistent with the established profile of VYVGART in patients with AChR-Ab seropositive gMG and other indications. No new safety concerns were identified.

ADAPT SERON Study Design

The Phase 3 ADAPT SERON study is a randomized, double-blind, placebo-controlled, multi-center study evaluating the safety and efficacy of efgartigimod in adults with AChR-Ab seronegative gMG (n=119) across North America, Europe, China, and the Middle East. Part A randomized participants (1:1) received 4 once-weekly infusions of efgartigimod IV or placebo, followed by a 5-week follow-up and primary analysis. Part B is an open-label extension: participants receive 2 fixed cycles of 4 once-weekly efgartigimod infusions (4-week interval between cycles); from cycle 3 onward, additional cycles could be started ≥1 week after the last administration of the previous cycle, based on clinical status. The primary endpoint is the MG-ADL total score change from baseline to day 29 in part A. Other scales of evaluation include QMG, MG-QoL 15r, MGC, and EQ-5D-5L VAS. Enrolled participants had a confirmed MG diagnosis by an independent panel of experts, and an MG-ADL total score of 5 or greater. Participants were on a stable dose of at least one gMG treatment prior to randomization, including acetylcholinesterase inhibitors, corticosteroids or nonsteroidal immunosuppressive drugs. Participants were eligible to enroll in ADAPT SERON if they were AChR-Ab seronegative, which included participants who are MuSK-Ab seropositive, LRP4-Ab seropositive, or triple seronegative.

MG-ADL is a validated measure of disease activity in patients living with myasthenia gravis, which evaluates the functional impact of symptoms on daily activities such as speaking, chewing, swallowing, breathing, and limb strength.

About AChR-Ab Seronegative Generalized Myasthenia Gravis (gMG)

Generalized myasthenia gravis (gMG) is a rare, chronic, neuromuscular autoimmune disease caused by pathogenic IgGs targeting the neuromuscular junction (NMJ), resulting in impaired neuromuscular transmission and debilitating and potentially life-threatening muscle weakness and chronic fatigue. Approximately 80% of patients with gMG have detectable antibodies against the AChR in sera, and these patients are diagnosed as AChR-Ab seropositive gMG. Approximately 20% of patients with gMG do not have detectable serum antibodies directed against AChR and are referred to as AChR-Ab seronegative gMG. These patients may have detectable autoantibodies targeting other NMJ proteins, such as muscle-specific tyrosine kinase (MuSK) and low-density lipoprotein receptor-related protein 4 (LRP4), or others. Anti-MuSK antibodies are detected in approximately 1-10% of patients with gMG, while anti-LRP4 antibodies are detected in approximately 1-5% of patients with gMG. About 10% of patients do not have any detectable autoantibodies against AChR, MuSK or LRP4. These triple seronegative patients have historically been excluded from studies and have a higher disease burden and unmet medical need compared to patients with detectable autoantibodies. Currently, there are no approved treatments available for patients with anti-LRP4 antibodies or for triple seronegative patients.

Important Safety Information 

What is VYVGART

^®

 
(efgartigimod alfa-fcab)? 

VYVGART is a prescription medicine used to treat a condition called generalized myasthenia gravis, which causes muscles to tire and weaken easily throughout the body, in adults who are positive for antibodies directed toward a protein called acetylcholine receptor (anti-AChR antibody positive). 
  
IMPORTANT SAFETY INFORMATION 
Do not use VYVGART if you have a serious allergy to efgartigimod alfa or any of the other ingredients in VYVGART. VYVGART can cause serious allergic reactions and a decrease in blood pressure leading to fainting. 
  
VYVGART may cause serious side effects, including: 

• Infection. VYVGART may increase the risk of infection. The most common infections were urinary tract and respiratory tract infections. Signs or symptoms of an infection may include fever, chills, frequent and/or painful urination, cough, pain and blockage of nasal passages/sinus, wheezing, shortness of breath, fatigue, sore throat, excess phlegm, nasal discharge, back pain, and/or chest pain. 
• Allergic Reactions (hypersensitivity reactions). VYVGART can cause allergic reactions such as rashes, swelling under the skin, and shortness of breath. Serious allergic reactions, such as trouble breathing and decrease in blood pressure leading to fainting have been reported with VYVGART.  
• Infusion-Related Reactions. VYVGART can cause infusion-related reactions. The most frequent symptoms and signs reported with VYVGART were high blood pressure, chills, shivering, and chest, abdominal, and back pain. 

  
Tell your doctor if you have signs or symptoms of an infection, allergic reaction, or infusion-related reaction. These can happen while you are receiving your VYVGART treatment or afterward. Your doctor may need to pause or stop your treatment. Contact your doctor immediately if you have signs or symptoms of a serious allergic reaction. 
  
Before taking VYVGART, tell your doctor if you: 

• take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines, 
• have received or are scheduled to receive a vaccine (immunization), or 
• have any allergies or medical conditions, including if you are pregnant or planning to become pregnant, or are breastfeeding. 

What are the common side effects of VYVGART? 

The most common side effects of VYVGART are respiratory tract infection, headache, and urinary tract infection.

These are not all the possible side effects of VYVGART. Call your doctor for medical advice about side effects. You may report side effects to the US Food and Drug Administration at 1-800-FDA-1088. 

Please see the full
 

Prescribing Information

 
for VYVGART and talk to your doctor. 

About VYVGART

VYVGART is a human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG autoantibodies. It is the first approved FcRn blocker in the United States, EU, China and Canada for the treatment of adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive and in Japan for the treatment of adults with gMG who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs).

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit  www.argenx.com  and follow us on LinkedIn, Instagram, Facebook, and YouTube.

This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation (Regulation 596/2014).

Media:

Colin McBean
[email protected]

Investors:

Alexandra Roy
[email protected]

FORWARD LOOKING STATEMENTS

The contents of this announcement include statements that are, or may be deemed to be, “forward-looking statements.” These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “commit,” and “continue,” and include statements argenx makes concerning the potential of VYVGART to meaningfully improve the lives of seronegative gMG patients who continue to face limited treatment options; its goal to expand the use of VYVGART in a broad spectrum of patients with myasthenia gravis; its commitment to improve the lives of people suffering from severe autoimmune diseases; and its aim to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx’s actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including but not limited to, the results of argenx’s clinical trials; expectations regarding the inherent uncertainties associated with the development of novel drug therapies; preclinical and clinical trial and product development activities and regulatory approval requirements; the acceptance of its products and product candidates by its patients as safe, effective and cost-effective; the impact of governmental laws and regulations, including tariffs, export controls, sanctions and other regulations on its business; its reliance on third-party suppliers, service providers and manufacturers; inflation and deflation and the corresponding fluctuations in interest rates; and regional instability and conflicts. A further list and description of these risks, uncertainties and other risks can be found in argenx’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx’s most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.

ORLANDO, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) — Innventure, Inc. (NASDAQ: INV) (“Innventure” or the “Company”), an industrial growth conglomerate, today announced it has entered into securities purchase agreements with four institutional investors for the purchase and sale of 11,428,572 shares of common stock for gross proceeds of approximately $40 million, before deducting placement agent fees and offering expenses. The offering is expected to close on or about January 14, 2026, subject to the satisfaction of customary closing conditions.

The Company expects to use the net proceeds from this offering to repay all outstanding obligations under the convertible debentures, subject to the terms of the securities purchase agreement, dated September 15, 2025, and for working capital and general corporate purposes, which may include the repayment of certain other outstanding indebtedness and the ability of the Company to exercise its right to receive equity in Accelsius in lieu of cash for Accelsius’ repayment of approximately $8 million principal amount of intercompany convertible debt and interest thereon.

Titan Partners is acting as sole placement agent for the offering.

The Offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-292427), previously filed with the Securities and Exchange Commission (the “SEC”) on December 23, 2025 and subsequently declared effective by the SEC on January 9, 2026. The final terms of the Offering will be disclosed in a prospectus supplement to be filed with the SEC, which will be available for free on the SEC’s website at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Innventure

Innventure (NASDAQ: INV), an industrial growth conglomerate, focuses on building companies with billion-dollar valuations by commercializing breakthrough technology solutions. By systematically creating and operating industrial enterprises from the ground up, Innventure participates in early-stage economics and provides industrial operating expertise designed for global scale. Innventure’s approach seeks to uniquely bridge the ”Valley of Death” between corporate innovation and commercialization through its distinctive combination of value-driven multinational partnerships, operational experience, and capital-intensive scale-up expertise.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements in this press release are “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited to, statements regarding the Offering, including the type of securities that may be issued in the Offering, the size, pricing or other terms of the Offering and the plan of distribution for the Offering; the estimated expenses of the Offering; the intended use of the net proceeds of the Offering; and the expected timing and closing of the Offering. Forward-looking statements are often identified by future or conditional words such as “plan,” “believe,” “expect,” “anticipate,” “intend,” “outlook,” “estimate,” “forecast,” “project,” “continue,” “could,” “may,” “might,” “possible,” “will,” “potential,” “predict,” “should,” “would” and other similar words and expressions (or the negative versions of such words or expressions), but the absence of these words does not mean that a statement is not forward-looking.

The forward-looking statements are based on the current assumptions and expectations of future events that are inherently subject to uncertainties and changes in circumstances and their potential effects and speak only as of the date of this press release. There can be no assurance that future developments will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the parties) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in the Company’s public filings made with the SEC and the following: (a) the Company’s ability to consummate the Offering; (b) the Company’s ability to use the net proceeds of the Offering in a manner that will increase the value of shareholders’ investment; (c) the Company’s and its subsidiaries’ ability to execute on strategies and achieve future financial performance, including their respective future business plans, expansion and acquisition plans or objectives, prospective performance and opportunities and competitors, revenues, products and services, pricing, operating expenses, market trends, liquidity, cash flows and uses of cash, capital expenditures, and the Company’s and its subsidiaries’ ability to invest in growth initiatives; (d) the implementation, market acceptance and success of the Company’s and its subsidiaries’ business models and growth strategies; (e) the Company’s and its subsidiaries’ future capital requirements and sources and uses of cash; (f) the Company’s ability to maintain control over its subsidiaries, (g) the Company’s access to funds under the Standby Equity Purchase Agreement with YA II PN, Ltd. due to certain conditions, restrictions and limitations set forth therein and in other agreements with YA II PN, Ltd.; (h) certain restrictions and limitations set forth in the Company’s debt instruments, which may impair the Company’s financial and operating flexibility; (i) the Company’s and its subsidiaries’ ability to generate liquidity and maintain sufficient capital to operate as anticipated; (j) the Company’s and its subsidiaries’ ability to obtain funding for their operations and future growth and to continue as going concerns; (k) the risk that the technology solutions that the Company and its subsidiaries license or acquire from third parties or develop internally may not function as anticipated or provide the benefits anticipated; (l) developments and projections relating to the Company’s and its subsidiaries’ competitors and industry; (m) the ability of the Company and its subsidiaries to scale the operations of their respective businesses; (n) the ability of the Company and its subsidiaries to establish substantial commercial sales of their products; (o) the ability of the Company and its subsidiaries to compete against companies with greater capital and other resources or superior technology or products; (p) the Company and its subsidiaries’ ability to meet, and to continue to meet, applicable regulatory requirements for the use of their respective products and the numerous regulatory requirements generally applicable to their businesses; (q) the outcome of any legal proceedings against the Company or its subsidiaries; (r) the Company’s ability to find future opportunities to license or acquire breakthrough technology solutions from multinational corporations or other third parties (“Technology Solutions Provider”) and to satisfy the requirements imposed by or to avoid disagreements with its current and future Technology Solutions Providers; (s) the risk that the launch of new companies distracts the Company’s management from its and its other subsidiaries’ operations; (t) the risk that the Company may be deemed an investment company under the Investment Company Act, which would impose burdensome compliance requirements and restrictions on its activities; (u) the ability of the Company and its subsidiaries to sufficiently protect their intellectual property rights and to avoid or resolve in a timely and cost-effective manner any disputes that may arise relating to its use of the intellectual property of third parties; (v) the risk of a cyber-attack or a failure of the Company’s or its subsidiaries’ information technology and data security infrastructure; (w) geopolitical risk and changes in applicable laws or regulations; (x) potential adverse effects of other economic, business, and/or competitive factors; (y) operational risks related to the Company and its subsidiaries that have limited or no operating history; and (z) limited liquidity and trading of the Company’s securities.

Except to the extent required by applicable law or regulation, the Company undertakes no obligation to update statements to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

Media Contact: Laurie Steinberg, Solebury Strategic Communications
[email protected]

Investor Relations Contact: Sloan Bohlen, Solebury Strategic Communications
[email protected]

TORONTO, Jan. 12, 2026 (GLOBE NEWSWIRE) — Visionary Holdings Inc. (Nasdaq: GV) (the “Company”) today announced the disclosure of its Annual Report on Form 20-F for the fiscal year ended March 31, 2025, outlining the Company’s strategic transformation, business restructuring progress, and financial performance.

During the reporting period, the Company continued to advance its transition from a traditional education- and real estate-focused business toward a diversified platform centered on health management, anti-aging and premium medical aesthetics, complemented by its AI-enabled education business. Emerging health-related businesses generated initial revenue contributions during the fiscal year, representing early progress in the Company’s strategic repositioning and providing potential new growth avenues over the medium to long term.

The complete and official Annual Report on Form 20-F is included as an attachment to this press release.

Financial Highlights

For fiscal year 2025, total revenue was USD 5.04 million, representing a year-over-year decrease of 46.2%, primarily attributable to the contraction of real estate leasing operations and changes in the education policy environment. Revenue composition included:

• Real estate leasing revenue of USD 2.80 million
• Education services revenue of USD 1.18 million
• Life sciences and health-related businesses, including health management, anti-aging, and medical aesthetics-related products and service-based offerings, generating USD 1.06 million

Revenue from emerging businesses accounted for approximately 21.1% of total revenue, indicating that the Company’s business restructuring has entered an early implementation stage.

The Company reported a net loss of USD 15.75 million, primarily reflecting one-time transformation-related investments, approximately USD 4.70 million in asset impairment charges, and financing-related costs, which management considers to be transitional in nature.

Gross margin improved modestly to 28.0%, with the education services segment achieving a gross margin of 64.4%, demonstrating relative stability in core operating efficiency. Cash flow from investing activities totaled USD 14.51 million, mainly resulting from asset dispositions that supported liquidity during the transformation period. Operating cash outflows decreased to USD 2.97 million, compared with USD 4.10 million in the prior fiscal year.

As of March 31, 2025, total assets amounted to USD 63.63 million. In response to certain loan defaults and approximately USD 54.50 million in negative working capital, the Company has continued to pursue measures including equity financing initiatives and negotiations with creditors regarding debt restructuring and extensions, with certain creditors having agreed to temporary extensions. Nevertheless, the Company continues to face liquidity and financing pressures, and management will continue to evaluate and implement prudent measures to improve its financial condition.

Business Developments and Strategic Transformation

Health Management Businesses

In the health management and anti-aging sector, the Company has pursued exploratory initiatives focused on health management and service-oriented offerings, including gastrointestinal health management and solutions. Through a business model combining platform development, strategic partners, and end-service delivery, the Company has advanced market testing and early-stage commercialization efforts in Asia. These initiatives remain subject to ongoing execution and validation.

Anti-Aging and Premium Medical Aesthetics Businesses

In the anti-aging and premium medical aesthetics sector, the Company is exploring service-driven medical aesthetics and health management solutions aligned with market demand in Asia and supported by North American medical resources.

During the reporting period, the Company established strategic collaborations with industry participants, including Jiangsu Yike Regenerative Medicine Technology Co., Ltd. and Anhui Weikang Kangling Medical Technology Co., Ltd. These collaborations are intended to support access to certain proprietary technologies and product resources with competitive industry positioning, and to facilitate the Company’s ongoing efforts to expand and develop its global premium medical aesthetics service network.

AI Education Business

The Company’s AI education business remained relatively stable. Through a hybrid online-offline model, the Company continued to offer Ontario Secondary School Diploma (OSSD) programs, vocational education, and academic pathway services, while maintaining cooperation with multiple Canadian public institutions to provide integrated education support services for international students.

CEO Commentary

Mr. Xiyong Hou, Chief Executive Officer of Visionary Holdings, commented:

“Fiscal year 2025 marked a critical phase in which the Company’s strategic transformation progressed from planning toward tangible execution. The initial revenue contributions generated by emerging businesses during the reporting period validated the practical feasibility of our transition toward health management, anti-aging, and premium medical aesthetics, and provided a foundation for subsequent development.

In the coming fiscal years, the Company will focus on high-potential segments within premium medical aesthetics and cellular rejuvenation-related businesses, advancing commercialization efforts and market expansion around Cellular Rejuvenation and Aesthetic Treatment-related products and services. Based on current market conditions, strategic planning, and execution assumptions, the Company believes it has the potential to drive this segment toward meaningful revenue scale over the next two years, subject to market dynamics, regulatory considerations, and execution progress.

At the same time, we remain committed to strengthening corporate governance and internal controls by enhancing financial and compliance capabilities, reinforcing enterprise-wide compliance practices, and improving audit committee oversight. Management will continue to execute with discipline and prudence, leveraging technological innovation, compliant operations, and service quality to support sustainable growth and create long-term value for shareholders.”

Outlook

Looking ahead, the Company intends to advance its development along the following directions:

• Continue to explore commercialization opportunities in health management, anti-aging, and premium medical aesthetics businesses, integrating global technology, market, and team resources through existing strategic collaborations and, subject to prudent evaluation, potential acquisitions or partnerships;
• Further optimize the AI education ecosystem by enhancing digital student management systems and steadily expanding marketing efforts in key Asian markets to support business stability and cash flow generation;
• Continue strengthening corporate governance and internal control systems, including the recruitment of experienced finance and compliance professionals, enhanced compliance training, and the normalization of audit committee operations, with the goal of improving financial reporting quality and operational transparency.

About Visionary Holdings Inc.

Visionary Holdings Inc. (Nasdaq: GV) is a technology-driven multinational enterprise focused on innovative education, AI applications, and high-tech healthcare solutions. Headquartered in Toronto, Canada, the Company operates through its subsidiaries across North America and Asia, driving technological advancement, cross-border innovation, and global health transformation.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will”, “expects”, “anticipates”, “future”, “intends”, “plans”, “believes”, “estimates”, “target”, “going forward”, “outlook,” “objective” and similar terms. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and which are beyond GV’s control, which may cause GV’s actual results, performance or achievements (including the RMB/USD value of its anticipated benefit to GV as described herein) to differ materially and in an adverse manner from anticipated results contained or implied in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in GV’s filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. GV does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

Contacts:

Visionary Holdings Inc.

Investor Relations
Email: [email protected]
Telephone: +1 905-305-1881
Website: http://www.visionary.holdings

A PDF accompanying this announcement is available at: http://ml.globenewswire.com/Resource/Download/d60032a2-5d2f-4e04-80e9-6cd0271dec39